antimicrobial activities against gramnegative bacteria e coli (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
antimicrobial activities against gramnegative bacteria e coli
Antimicrobial Activities Against Gramnegative Bacteria E Coli, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 22300 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antimicrobial+activities+against+gramnegative+bacteria+e+coli/Bacteria/pm32623216-204-13-23
Average 99 stars, based on 22300 article reviews
Antimicrobial Activities Against Gramnegative Bacteria E Coli, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 22300 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antimicrobial+activities+against+gramnegative+bacteria+e+coli/Bacteria/pm32623216-204-13-23
Average 99 stars, based on 22300 article reviews
antimicrobial activities against gramnegative bacteria e coli - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
In Vitro:Article Title: Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives. Article Snippet: Herein we report the design, synthesis and biological evaluation of structurally modified ciprofloxacin, norfloxacin and moxifloxacin standard drugs, featuring amide functional groups at C-3 of the fluoroquinolone scaffold.. In vitro antimicrobial testing against various Gram-positive bacteria, Gram-negative bacteria and fungi revealed potential antibacterial and antifungal activity.. Hybrid compounds 9 (MIC 0.2668 ± 0.0001 mM), 10 (MIC 0.1358 ± 00025 mM) and 13 (MIC 0.0898 ± 0.0014 mM) had potential antimicrobial activity against a fluoroquinolone-resistant Escherichia coli clinical isolate, compared to ciprofloxacin (MIC 0.5098 ± 0.0024 mM) and norfloxacin (MIC 0.2937 ± 0.0021 mM) standard drugs. Bacteria:Article Title: Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives. Article Snippet: Herein we report the design, synthesis and biological evaluation of structurally modified ciprofloxacin, norfloxacin and moxifloxacin standard drugs, featuring amide functional groups at C-3 of the fluoroquinolone scaffold.. In vitro antimicrobial testing against various Gram-positive bacteria, Gram-negative bacteria and fungi revealed potential antibacterial and antifungal activity.. Hybrid compounds 9 (MIC 0.2668 ± 0.0001 mM), 10 (MIC 0.1358 ± 00025 mM) and 13 (MIC 0.0898 ± 0.0014 mM) had potential antimicrobial activity against a fluoroquinolone-resistant Escherichia coli clinical isolate, compared to ciprofloxacin (MIC 0.5098 ± 0.0024 mM) and norfloxacin (MIC 0.2937 ± 0.0021 mM) standard drugs. |